630 related articles for article (PubMed ID: 23257362)
1. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
Verhaak RG; Tamayo P; Yang JY; Hubbard D; Zhang H; Creighton CJ; Fereday S; Lawrence M; Carter SL; Mermel CH; Kostic AD; Etemadmoghadam D; Saksena G; Cibulskis K; Duraisamy S; Levanon K; Sougnez C; Tsherniak A; Gomez S; Onofrio R; Gabriel S; Chin L; Zhang N; Spellman PT; Zhang Y; Akbani R; Hoadley KA; Kahn A; Köbel M; Huntsman D; Soslow RA; Defazio A; Birrer MJ; Gray JW; Weinstein JN; Bowtell DD; Drapkin R; Mesirov JP; Getz G; Levine DA; Meyerson M;
J Clin Invest; 2013 Jan; 123(1):517-25. PubMed ID: 23257362
[TBL] [Abstract][Full Text] [Related]
2. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
3. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
4. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
5. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
[TBL] [Abstract][Full Text] [Related]
8. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
[TBL] [Abstract][Full Text] [Related]
9. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
[TBL] [Abstract][Full Text] [Related]
10. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
14. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
15. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
[TBL] [Abstract][Full Text] [Related]
16. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
Winterhoff B; Hamidi H; Wang C; Kalli KR; Fridley BL; Dering J; Chen HW; Cliby WA; Wang HJ; Dowdy S; Gostout BS; Keeney GL; Goode EL; Konecny GE
Gynecol Oncol; 2016 Apr; 141(1):95-100. PubMed ID: 27016234
[TBL] [Abstract][Full Text] [Related]
19. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
20. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.
Zhang S; Jing Y; Zhang M; Zhang Z; Ma P; Peng H; Shi K; Gao WQ; Zhuang G
Sci Rep; 2015 Nov; 5():16066. PubMed ID: 26530441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
